Delta Dental Invests in Interleukin Genetics to Advance Periodontal Disease Susceptibility Risk Test
Michigan-based Delta Dental invests 3 million USD in Interleukin Genetics to further research and develop their periodontal disease susceptibility risk test. The risk test forms part of Interleukin Genetics’ Inherent Health and Periodontal Disease Test (PST) product development, supported by Delta Dental Plan of Michigan Inc.
The periodontal disease susceptibility risk test is designed to classify patients based on their predisposition or susceptibility to developing periodontal disease and forms part of the PST. Such tests aim to provide information for treatment frequency and duration, such as teeth cleaning.
Working in collaboration with Interleukin Genetics, the University of Michigan School of Dentistry is analyzing patient data, which dates back from 15 years ago and is provided by Delta Dental. The analysis is aimed at revealing how effective the test is as a predictor of periodontal disease risk and scheduled teeth cleaning benefits.
CEO Lewis Bender of Interleukin Genetics says: “If the data demonstrates that low-risk patients do not benefit from the second cleaning, that’s big news. If it demonstrates that high-risk patients would benefit from three or four cleanings a year, that’s big news. If it demonstrates (neither of those), that’s big news, too, but in a non-positive way”.
Join this Discussion
